1. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Issue 4 (31st October 2013) Authors: Denison, H.; Nilsson, C.; Löfgren, L.; Himmelmann, A.; Mårtensson, G.; Knutsson, M.; AL‐Shurbaji, A.; Tornqvist, H.; Eriksson, J. W. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 4(2014:Apr.) Page Start: 334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first‐time‐in‐human single‐dose study. Issue 2 (30th September 2012) Authors: Denison, H.; Nilsson, C.; Kujacic, M.; Löfgren, L.; Karlsson, C.; Knutsson, M.; Eriksson, J. W. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 2(2013:Feb.) Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗